Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchUpdates on mechanism of action and clinical efficacy of risedronate in osteoporosisTreatment of primary osteoporosis in menBisphosphonate drug holiday: choosing appropriate candidatesEpidemiology and management of osteoporosis in the People's Republic of China: current perspectivesDenosumab for the treatment of osteoporosisAn overview on the treatment of postmenopausal osteoporosisAtypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and PreventionThe epidemiology and management of postmenopausal osteoporosis: a viewpoint from BrazilBisphosphonates: from bench to bedsideUpdate on bazedoxifene: a novel selective estrogen receptor modulatorN-phenacylthiazolium bromide reduces bone fragility induced by nonenzymatic glycationAn overview and management of osteoporosisTeriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.Odanacatib for the treatment of postmenopausal osteoporosis.Treatment of postmenopausal osteoporosis with odanacatib.Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment.The association between compliance and persistence with bisphosphonate therapy and fracture risk: a reviewBone mass is preserved and cancellous architecture altered due to cyclic loading of the mouse tibia after orchidectomy.Calcium citrate and vitamin D in the treatment of osteoporosis.National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.UK clinical guideline for the prevention and treatment of osteoporosisThe assessment of fracture risk.Adoption of once-monthly oral bisphosphonates and the impact on adherence.Lateral Femoral Bowing and the Location of Atypical Femoral Fractures.Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesIntermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats.Fracture liaison services: do they reduce fracture rates?Safety of drugs used in the treatment of osteoporosis.Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Efficacy of ibandronate: a long term confirmation.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal womenLong-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis
P2860
Q24612411-CAFDFAF0-3CC6-48A5-B0C0-242FF19C8268Q24644708-B8A77E37-83E7-4DD9-8604-D736ED740A51Q24680238-33ACF413-DE56-4F36-8152-94A7E7A9E097Q26782621-E62CBF2B-F70E-4103-AE1F-3994B8E5C49BQ26864549-5A8D7952-24EC-4F78-8B1E-9944B9326AE7Q26991748-874B85CA-F511-4BDE-859D-A6C22066586DQ27004682-0E3185DC-B3AC-4B60-9593-34390939BF2BQ27005978-D0ED12DC-AE17-4A6E-9F43-44F1226484C8Q27009275-17F6A345-982E-4336-B67D-48460392C3EEQ27013070-FEB0509F-4831-4B79-91F7-06999FE04334Q28079133-F5632B5F-F682-4445-9C29-B4048B4E2FC4Q28080673-1028EE0D-6716-4A53-B618-5F82B66EEEE1Q28251212-8A5280CE-D044-40EF-BB70-F8EDB2EA068CQ28258998-98371989-8A6C-4A25-A2B6-8FEF2DDBA38FQ28541226-0ECD34B1-FDB5-4858-B8D5-461DBB7C2B99Q30235274-1861AFD5-A2FD-476D-9307-A1F9D8503D88Q30627873-36A2A0DA-4AD0-4AC8-A4FD-4F230E064C35Q30683504-9DA615F9-D042-490D-979A-5C42BCF19DB7Q30740996-65E66A9F-7C7F-44AB-B358-69B6E1D5C321Q30755058-60F424FB-AF73-42C4-9C60-B945D0586B32Q30870287-DB75D4D7-7BA3-4B1E-96F7-3AF7BCF5DFC0Q33300458-10520C35-DD03-45E4-A14D-C09097C29CFBQ33330451-EDB50900-BB74-413E-8257-B1C49F65F28FQ33449783-7A3E1A48-FFCF-4CED-ACA8-E575F17D68CFQ33572610-E8A34AB3-AAD4-4DD0-819C-D8CAAF06BD7BQ33581078-506E82F3-96B8-4A24-90D9-1FC9D4B73C59Q33685092-DD218283-F8BE-4E0E-878F-786B4D6BE29BQ33701964-053EE811-3B8E-469A-8C29-CC7D673ED477Q33781081-2289A0E0-6DD5-4220-9EA4-D63E266FCB2EQ33819111-C5BDB86E-A926-45FE-8033-1380360F91CFQ33841826-9B4E16AB-DFFB-49A1-AA37-6A04F3C2EBE6Q33887646-03B7F626-2A23-4742-8062-62837C4D4D15Q33949479-CEBC1AB2-B4FB-44CF-B778-331241D86227Q33958113-7C786C0D-9CB4-45DD-8A18-98E1F258769AQ33965657-74D9EEDE-551F-4DA0-B8F4-3B4A43DD972EQ34009569-5FF5AEDA-AF72-4291-9A33-65B824B6A1A9Q34018048-BF60E4D6-0232-44A6-A43D-715B707D388AQ34029509-2FC35F34-37B6-40FC-BEA8-76F39C52D6DDQ34041189-B847559A-48E9-490C-9F7D-BB6E39024EFCQ34042003-17649FA8-C615-4FE3-8F02-8E2971AA7E60
P2860
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Effects of oral ibandronate ad ...... n postmenopausal osteoporosis.
@en
Effects of oral ibandronate ad ...... n postmenopausal osteoporosis.
@nl
type
label
Effects of oral ibandronate ad ...... n postmenopausal osteoporosis.
@en
Effects of oral ibandronate ad ...... n postmenopausal osteoporosis.
@nl
prefLabel
Effects of oral ibandronate ad ...... n postmenopausal osteoporosis.
@en
Effects of oral ibandronate ad ...... n postmenopausal osteoporosis.
@nl
P2093
P2860
P356
P1476
Effects of oral ibandronate ad ...... in postmenopausal osteoporosis
@en
P2093
Arne Hoiseth
Charles H Chesnut
Claus Christiansen
Dieter Felsenberg
Hermann Huss
Jacob A Stakkestad
Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)
Pierre D Delmas
Ralph C Schimmer
P2860
P304
P356
10.1359/JBMR.040325
P577
2004-03-29T00:00:00Z